Literature DB >> 19513548

Axin induces cell death and reduces cell proliferation in astrocytoma by activating the p53 pathway.

Li-Ying Zhang1, Jing Ye, Feng Zhang, Fan-Fan Li, Hang Li, Yu Gu, Fang Liu, Guang-Sheng Chen, Qing Li.   

Abstract

Astrocytic tumors are the most common brain tumors with various genetic defects. As a tumor suppressor gene, Axin could control cell death and growth. Axin possesses a separate domain that directly interacts with p53 and regulates the activity of p53 pathway. Our aims were to elucidate the effects of Axin on the progression of astrocytoma. We examined the expression of Axin in 96 cases of astrocytoma using immunohistochemistry. The apoptotic index, proliferactive acitivity and the expression levels of p53 and its downstream genes, p21 and Cyclin D1, were evaluated in the C6 astrocytoma cells with overexpression or silencing of Axin. The results showed the levels of Axin correlated significantly inversely with the grades of astrocytoma (R=-0.286, P<0.05) and correlated negatively with Ki-67 labeling index (R=-0.227, P<0.05). Overexpression of Axin in C6 cells induces cell death, and reduces the cell proliferation, up-regulates the expression of p53. Silencing of Axin reduces p53 expression. The p53 inhibitor, pifithrin-alpha, was able to counteract the effect of Axin in C6 cells. Our data demonstrate that the expression of Axin is associated negatively with the progression of astrocytoma. In conclusion, Axin induces cell death and reduces cell proliferation, partially by activating the p53 pathway in astrocytoma cells. This knowledge is helpful in understanding the role of Axin in the progression of astrocytoma.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19513548     DOI: 10.3892/ijo_00000309

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  6 in total

Review 1.  Wnt/beta-catenin signaling in glioma.

Authors:  Kailiang Zhang; Junxia Zhang; Lei Han; Peiyu Pu; Chunsheng Kang
Journal:  J Neuroimmune Pharmacol       Date:  2012-03-28       Impact factor: 4.147

Review 2.  Current Understanding on EGFR and Wnt/β-Catenin Signaling in Glioma and Their Possible Crosstalk.

Authors:  Indranil Paul; Seemana Bhattacharya; Anirban Chatterjee; Mrinal K Ghosh
Journal:  Genes Cancer       Date:  2013-11

3.  Identification and characterization of a small-molecule inhibitor of Wnt signaling in glioblastoma cells.

Authors:  Alessandra De Robertis; Silvia Valensin; Marco Rossi; Patrizia Tunici; Margherita Verani; Antonella De Rosa; Cinzia Giordano; Maurizio Varrone; Arianna Nencini; Carmela Pratelli; Tiziana Benicchi; Annette Bakker; Jeffrey Hill; Kanda Sangthongpitag; Vishal Pendharkar; Boping Liu; Fui Mee Ng; Siew Wen Then; Shi Jing Tai; Seong-Moon Cheong; Xi He; Andrea Caricasole; Massimiliano Salerno
Journal:  Mol Cancer Ther       Date:  2013-04-25       Impact factor: 6.261

4.  LSDP5 enhances triglyceride storage in hepatocytes by influencing lipolysis and fatty acid β-oxidation of lipid droplets.

Authors:  Hang Li; Yue Song; Li-Jun Zhang; Yu Gu; Fan-Fan Li; Shu-Yi Pan; Li-Na Jiang; Fang Liu; Jing Ye; Qing Li
Journal:  PLoS One       Date:  2012-06-01       Impact factor: 3.240

5.  Shikonin Inhibits the Migration and Invasion of Human Glioblastoma Cells by Targeting Phosphorylated β-Catenin and Phosphorylated PI3K/Akt: A Potential Mechanism for the Anti-Glioma Efficacy of a Traditional Chinese Herbal Medicine.

Authors:  Feng-Ying Zhang; Yi Hu; Zhong-You Que; Ping Wang; Yun-Hui Liu; Zhen-Hua Wang; Yi-Xue Xue
Journal:  Int J Mol Sci       Date:  2015-10-09       Impact factor: 5.923

6.  Wnt pathway antagonists, SFRP1, SFRP2, SOX17, and PPP2R2B, are methylated in gliomas and SFRP1 methylation predicts shorter survival.

Authors:  Aleksandra Majchrzak-Celińska; Marta Słocińska; Anna-Maria Barciszewska; Stanisław Nowak; Wanda Baer-Dubowska
Journal:  J Appl Genet       Date:  2015-09-04       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.